RxDoctor Payments Data

Aleksandr Wirga, MD

Psychiatry · Long Beach, CANPI 1124096409

Payments from drug & device makers

$690in general payments, 2019–2025

Across 24 payments — averaging $28.73 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Otsuka America Pharmaceutical, Inc.$211
  • Johnson & Johnson$142
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$134
  • AbbVie$91
  • Sage Therapeutics, LLC$44
  • Axsome Therapeutics, Inc.$30
  • plus $38 from 2 others

What the payments were for

  • Food & beverage$690100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$690 in reported general payments places this provider in the 70th percentile of 4,954 psychiatry providers in California.

See all psychiatry providers in California

Medicare billing

Part B allowed, 2024
$44,431
Medicare patients
90
Services billed
374

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
IngrezzaValbenazine Tosylate16$129,282
Abilify MaintenaAripiprazole18$51,549
Lurasidone Hcl96$28,401
CaplytaLumateperone Tosylate12$19,059
Aripiprazole67$5,833
Ziprasidone Hcl38$4,769
Doxepin Hcl16$3,867
CymbaltaDuloxetine Hcl11$3,087
Desvenlafaxine Succinate ErDesvenlafaxine Succinate23$2,677
Quetiapine Fumarate131$2,675
Bupropion XlBupropion Hcl102$2,410
Clozapine19$2,002
Duloxetine Hcl65$1,707
Quetiapine Fumarate ErQuetiapine Fumarate44$1,642
Trazodone Hcl154$1,351

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Otsuka America Pharmaceutical, Inc.Abilify Maintena$211$51,54918 claims
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta$134$19,05912 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 4,954 psychiatry providers in California.

Other psychiatry in Long Beach

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →